Duvelisib
[7] Common side effects include diarrhea, low white blood cells, rash, feeling tired, fever, and muscle pains.[9] Duvelisib, also known as IPI-145, was discovered by Intellikine,[10] a company founded in September 2007 based on biochemistry research from the lab of Kevan Shokat at the University of California San Francisco.[7] The serious side effects included infections, diarrhea, inflammation of the intestine and lungs, skin reactions, and elevated liver enzyme levels in the blood.[18][19] In April 2022, the FDA withdrew the approval of duvelisib for relapsed or refractory follicular lymphoma on request of its then owner, Secura Bio.[20] Duvelisib is intended to be used in people who have received at least two prior systemic therapies, and carries a black box warning due to the risk of fatal/serious toxicities: infections, diarrhea or colitis, cutaneous reactions and pneumonitis.